Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc., a Delaware corporation, on September 3, 2026. The report discloses an upcoming corporate presentation and provides a snapshot of the company's outstanding share count and market capitalization as of September 2, 2026.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. However, it discloses the following market data as of September 2, 2026:
- Outstanding Common Stock: 600,736 shares
- Aggregate Market Value: Approximately $5.9 million
- Trading Venue: Nasdaq Capital Market (Symbol: BIAF)
Material Changes
The filing does not report material changes to financial performance, operations, or capital structure compared to prior periods. The primary disclosure is the scheduling of an investor presentation event.
Outlook, Management Commentary, and Risks
Upcoming Event: President and CEO Maria Zannes is scheduled to present a corporate update and hold one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026. A press release detailing this event is attached as Exhibit 99.1.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard disclosures inherent in an 8-K for an emerging growth company.
Key Facts for Investor Verification
- Verify the content of the corporate update to be presented at the H.C. Wainwright conference on September 14-16, 2026.
- Confirm the current share count of 600,736 and the implied share price of approximately $9.82 (derived from $5.9 million market cap) as of September 2, 2026.
- Review the attached press release (Exhibit 99.1) for any additional strategic announcements not detailed in the 8-K text.